RECRUITING

WiseApp for Spanish Speakers Living with HIV

Conditions

HIV Infections Acquired Immune Deficiency Syndrome Sexually Transmitted Diseases, Viral People living with HIV (PLWH)Antiretroviral therapy (ART)Mobile Health Spanish Speakers Latinos

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to conduct a 12-month randomized controlled trial to adapt the mobile app, WiseApp, and a smart pill dispenser for Spanish-speaking people living with HIV (PLWH) in the New York City (NYC) area and La Romana, Dominican Republic (DR). The study will assess the efficacy and sustainability of WiseApp as well as identify barriers with its widespread use among Spanish speakers. With disproportionately high rates of HIV in the New York City area and the Dominican Republic, this project seeks to identify distinct contextual factors related to Spanish speaking people living with HIV and increase the likelihood of engagement with technology and improvements in clinical outcomes.

Official Title

WiseApp for Spanish-Speaking Latino Persons Living with HIV (PLWH) in the United States (US) and the Dominican Republic (DR)

Quick Facts

Study Start:2023-03-01

Study Completion:2027-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05398185

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Able to speak, read, and write in Spanish; * Aged ≥18 years; * Willing to participate in any assigned arm of the intervention; * Have an HIV-1 RNA level \>50 copies/mL; * Own a smartphone (DR participants who are eligible but without access to a smartphone will get one as part of the study at the time of enrollment); and * Ability and willingness to provide informed consent for study participation and consent for access to medical records.	* Reside in a nursing home, prison, and/or receiving in-patient psychiatric care at time of enrollment; * Terminal illness with life expectancy \<6 months; * Planning to move out of the area in the next 12 months; * A cognitive state minimum score measured by the Mini-Mental State Examination (MMSE) to ensure participants are oriented to time and place. * Spouses/partners may not enroll in this study. The study will be limited to only 1 person from the same family/domestic household.

Inclusion Criteria

Exclusion Criteria

* Able to speak, read, and write in Spanish;
* Aged ≥18 years;
* Willing to participate in any assigned arm of the intervention;
* Have an HIV-1 RNA level \>50 copies/mL;
* Own a smartphone (DR participants who are eligible but without access to a smartphone will get one as part of the study at the time of enrollment); and
* Ability and willingness to provide informed consent for study participation and consent for access to medical records.

* Reside in a nursing home, prison, and/or receiving in-patient psychiatric care at time of enrollment;
* Terminal illness with life expectancy \<6 months;
* Planning to move out of the area in the next 12 months;
* A cognitive state minimum score measured by the Mini-Mental State Examination (MMSE) to ensure participants are oriented to time and place.
* Spouses/partners may not enroll in this study. The study will be limited to only 1 person from the same family/domestic household.

Contacts and Locations

Study Contact

Rebecca Schnall, PhD, MPH

CONTACT

212-342-6886

rb897@columbia.edu

Felix Olaya, MPH

CONTACT

fmo2110@cumc.columbia.edu

Principal Investigator

Rebecca Schnall, PhD, MPH

PRINCIPAL_INVESTIGATOR

Columbia University

Study Locations (Sites)

Columbia University Irving Medical Center

New York, New York, 10032

United States

Collaborators and Investigators

Sponsor: Columbia University

Rebecca Schnall, PhD, MPH, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-01

Study Completion Date2027-01

Study Record Updates

Study Start Date2023-03-01

Study Completion Date2027-01

Terms related to this study

Keywords Provided by Researchers

People living with HIV (PLWH)
Antiretroviral therapy (ART)
Mobile Health
Spanish Speakers
Latinos

Additional Relevant MeSH Terms

HIV Infections
Acquired Immune Deficiency Syndrome
Sexually Transmitted Diseases, Viral